The clinical development program will include the treatment of hospital- and community-acquired Gram-positive infections...Enobia Pharma Inc., of Montreal, said preclinical data demonstrated that its enzyme replacement therapy (ERT) for hypophosphatasia appeared to heal bones that have been severely weakened by the disease...Sinovac Biotech Ltd., of Beijing, China, has begun clinical trials in Ukraine for its inactivated hepatitis A vaccine, Healive

One of the patients with a CR, who had failed multiple prior therapies including high-dose dexamethasone, presented with extensive kidney involvement with leukemia and kidney failure without bone marrow relapse...PainCeptor Pharma, of Montreal, said a study showed PPC-5650, an ASIC1a antagonist, reduced thermal and mechanical hyperalgesia in a human inflammatory pain model

closed a $19 million Series B expansion round to advance its midstage clinical programs for cardiovascular and inflammatory diseases...Proceeds will be used for clinical trials of multiple sclerosis vaccine Tovaxin...Phase IIb data are expected next month.

The results confirmed previous clinical findings that DG041 inhibits platelet aggregation without increasing bleeding time as monotherapy, and demonstrated that in combination with clopidogrel alone, as well as with clopidogrel and aspirin, DG041 provided additional antiplatelet effect without prolonging bleeding time...EUSA Pharma, of Oxford, UK, said new data show that use of Caphosol, an advanced oral electrolyte solution, resulted in both favorable impact on rates and severity of oral mucositis

Revimmune contains an approved chemotherapeutic drug (cyclophosphamide) and is designed to provide an ultra-high dose, pulsed intravenous administration for four hours daily over four days...Tranzyme Pharma, of Research Triangle Park, N.C., said it completed a Phase I study of oral ghrelin agonist TZP-1002, a prokinetic agent in development for mild to moderate gastroparesis

Inovio Biomedical Corp., of San Diego, said a clinical study of an experimental DNA-based prostate cancer vaccine has reaffirmed that, post-treatment, the therapy is safe and well tolerated...There have been no significant adverse effects, and a clinical effect was demonstrated with reduction in daily insulin requirement for up to six months follow-up with satisfactory control of blood glucose...Tranzyme Pharma, of Research Triangle Park, N.C., reported positive results from a Phase IIa study of first

Among the data emerging at this year's American Society of Clinical Oncology meeting in Chicago were results showing that a combination treatment regimen of Celgene Corp.'s Revlimid (lenalidomide) and Millennium Pharmaceuticals' Velcade (bortezomib), along with dexamethasone, yielded a complete response rate of 35 percent and an overall response rate of 100 percent in newly diagnosed myeloma patients...Antisense Pharma GmbH, of Regensburg, Germany, reported a two-year survival rate of more than 80

7TM Pharma A/S, of Horsholm, Denmark, reported positive results from two clinical studies of obesity drug TM30339, a drug designed to work via the Y4 receptor to mimic a natural satiety signal from the gastrointestinal tract involved in the regulation of food...Patients in the high-dose (15 mg twice daily) group showed a 62.4 percent improvement from baseline vs

The second phase will compare a higher dose of Locteron to PEG-Intron, each in combination with ribavirin, patients who have failed prior treatment...RFS Pharma LLC, of Atlanta, said the combination of Amdoxovir (DAPD) and Retrovir (zidovudine, GlaxoSmithKline plc) produced a synergistic decline in viral load in a Phase II trial

The study also will measure the effect of Soliris on other clinical manifestations of PNH, including blood transfusion requirements, thromboses and kidney function...GTC's partner LEO Pharma A/S, of Ballerup, Denmark, has begun launching the product in Europe...MAP Pharmaceuticals Inc., of Mountain View, Calif., has initiated a Phase III clinical trial evaluating Unit Dose Budesonide (UDB), its nebulized version of budesonide, for the potential treatment of pediatric asthma

DuoCort Pharma AB, of Helsingborg, Sweden, said enrollment is complete in the pivotal Phase II/III clinical trial evaluating 5-mg and 20-mg DuoCort dual-release hydrocortisone tablets for the treatment of adrenal insufficiency - the inability of the body to produce sufficient amounts of the essential hormone cortisol...The Phase I/II clinical trial is expected to enroll approximately 120 NHL subjects who have undergone two or more prior therapies and have relapsed or refractory disease

Cardiome Pharma Corp., of Vancouver, British Columbia, said interim results from its Phase IIb trial with oral vernakalant to prevent recurrence of atrial fibrillation, which originally were due in the fourth quarter of this year, will not be disclosed until March 2008, with final data in the middle of next year...Based on those results, NovaBay started a second Phase I trial to test the safety of NVC-422 at a higher dose and expects to have results from that study by early 2008...The firm expects to

Remaining funds will support clinical trials of AEGR-733 and AEGR-427 (implitapide), both of which are small-molecule microsomal triglyceride transfer protein (MTP) inhibitors for hyperlipidemia, as well as preclinical studies and general corporate purposes...In June, the agency instituted a partial clinical hold on MTP inhibitor trials longer than six months, although Aegerion noted that none of its planned Phase II trials will exceed six months and it has obtained a waiver for its planned Phase

The compounds could enter human clinical trials in late 2008...In a Phase I clinical study, an ovarian cancer patient with the clear-cell subtype experienced a durable partial response to the compound lasting over three years after failing three prior chemotherapy regimens...Jennerex Biotherapeutics, of San Francisco, presented clinical data from a Phase I/II trial of JX-594, its targeted lytic and immunostimulatory armed virus therapy, demonstrating efficacy in 10 of the 13 evaluable patients with

Notably, when the high-dose injections were continued for 52 days, the mice retained their healthy growth and appearance, while all untreated mice died within 24 days...Enobia has a contract with Laureate Pharma Inc., of Princeton, N.J., to produce the enzyme for clinical trials

Kiadis Pharma BV, of Groningen, the Netherlands, enrolled the last patient in its Phase I/II trial of Rhitol in steroid-resistant or intolerant chronic graft-vs.-host disease following bone marrow transplantation...A total of 20 patients were randomized to receive either low or high doses of Rhitol, a small-molecule drug designed to selectively accumulate in reactive immune cells and to eliminate those cells upon photo-activation...clinical sites participating in its ViaCyte pivotal trial from three

Among the new information was that ATC demonstrated significant clinical activity against a range of drug-resistant HIV, including HIV strains harboring the lamivudine-resistance mutation (M184...Tranzyme Pharma Inc., of Research Triangle Park, N.C., started a Phase IIb trial of TZP-101, a ghrelin agonist, in postoperative ileus...Uluru Inc., of Addison, Texas, began a clinical study to evaluate the mobility of severely burned joints treated with its Hydrogel Nanoparticle Wound Dressing

Medicure licensed Aggrastat, which is approved for acute coronary syndrome, from MGI Pharma Inc., of Bloomington, Minn. (See BioWorld Today, Aug. 10, 2006...Peregrine Pharmaceuticals Inc., of Tustin, Calif., has submitted a clinical protocol with the drug controller general of India for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small-cell lung cancer...Results showed that the incidence of VTE was 20 percent, 15 percent and 10 percent in the low-dose group of

Pfizer's investment in the offering is about $6.5 million, and adds to the 22.5 million ordinary shares purchased by the pharma firm at the time of the agreement. (See BioWorld Today, April 5, 2007.) According to pSivida's prospectus, the company expects net proceeds to total $16.3 million, which will add to the $7.4 million in the bank as of March 31...Money also will be used to advance clinical development programs, pursue additional in-licensing opportunities and for other general corporate